This product is specifically developed for the large-scale production of AAV in suspension systems. It is an optimized and modified linear polyethylenimine (Polyethylenimine Linear, PEI). The product is synthesized purely through chemical processes, free from animal-derived components, and has low cytotoxicity. It also offers broad applicability across various AAV serotypes. With high DNA loading capacity, a low transfection complex ratio, and high complex stability, this product facilitates large-scale AAV production.
The product is manufactured in accordance with GMP requirements and is provided in the form of a sterile liquid.
Applications Production of AAV Viral Vectors
Specificationsrnrnrnrn
Form
liquid
Properties
Polyethylenimine Linear (PEI)
Virus Type
AAV
Componentsrnrn
Components No.
Name
40824ES10
40824ES60
40824ES80
40824
Hieff Trans™ PEI AAV Transfection Reagent-GMP
10 mL
100 mL
1 L
Features
Significant Increase in Virus Titer: The product achieves a substantial increase in virus yield, with approximately a 2-fold increase in virus titer for multiple serotypes, including AAV2, AAV5, AAV8, and AAV9.
Reduced Usage Cost: By reducing the amount of transfection reagent by 50% while maintaining high yield, the product effectively lowers production costs.
Storage
Hieff Trans™ PEI AAV Transfection Reagent-GMP products should be stored at 2-8℃ for 2 year.
Hieff Trans™ PEI AAV showing ultra trans-effciency compared with top PEIs. AAV2, AAV5, AAV8, and AAV9 were produced in suspension 293F cells, with a DNA dosage of 1 µg per million cells. The virus was harvested 72 hours post-transfection, and the viral supernatant was analyzed.
Hieff Trans™ PEI showing low inputs. AAV9 was produced in suspension 293F cells with different input of Ultra-PEI (Left, Plasmids input: 0.5 μg) or Plasmids (Right, Ultra-PEI input 0.6 μL) dosages per million cells. The virus was harvested 72 hours post-transfection.